The American Medical Association Substance Use and Pain Care Task Force continues to advance evidence-based recommendations for policymakers and physicians to help end the nation’s drug-related overdose and death epidemic. Physicians’ positive actions, however, are limited by an insufficient focus on meaningful policy implementation and enforcement to support affordable, accessible, evidence-based care for patients with a substance use disorder, pain, or access to harm reduction services such as naloxone, syringe services programs and fentanyl test strips.
We urge all stakeholders to come together to help reverse this national epidemic.
Read more in the 2022 Overdose Epidemic Report.
From 2012 to 2021, medications to treat opioid use disorder (MOUD) increased 104%; from 2020 to 2021, however, it only increased 1.6%.
From 2016 to 2021, naloxone prescriptions dispensed from pharmacies increased from almost 134,000 to nearly 1.2 million prescriptions.
From 2012 to 2021, every state in the nation saw a large decrease of prescription opioids dispensed from retail pharmacies.
Physicians and other authorized users queried state prescription drug monitoring programs (PDMPs) more than 1.1 billion times in 2021
The AMA and Manatt Health 2022 State Toolkit identifies more than 400 state laws, regulations, policy guidance and other select national actions being implemented to help end the nation's drug overdose epidemic.
Issued September 2021
Join the AMA today and help us lead the effort
to reverse the nation’s opioid epidemic.